Survival of Patients with Malignant Pleural Effusion: A Single Center Study
(Survival of Patients with Malignant Pleural Effusion: A Single Center Study)

Title Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Title Original Survival of Patients with Malignant Pleural Effusion: A Single Center Study
Author Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif
Publication Date: 1401
Publication Place Shiraz University of Medical Sciences - Shiraz University of Medical Sciences
Subject malignant, pleural effusion, survival
Type Periodical
Language Arabic
Digital Yes
Manuscript No
Library: Universitat de Girona
Library Asset ID EISSN: 2322-4339, DOI: 10.30476/smsj.2023.95854.1354
Record ID cdi_doaj_primary_oai_doaj_org_article_ea74ee8bfe754a35aed51313fc821cc2
Library Location Available Online
Date 1401
Sample Text Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion.
Universitat de Girona - Ottoman library catalog search Universitat de Girona

Survival of Patients with Malignant Pleural Effusion: A Single Center Study

(Survival of Patients with Malignant Pleural Effusion: A Single Center Study)
Author Mohammad Javad Fallahi, Alireza Rezvani, Zainab Al-Saif
Publication Date 1401
Publication Place Shiraz University of Medical Sciences - Shiraz University of Medical Sciences
Subject malignant, pleural effusion, survival
Type Periodical
Language Arabic
Digital Yes
Manuscript No
Library Universitat de Girona
Library Asset ID EISSN: 2322-4339, DOI: 10.30476/smsj.2023.95854.1354
Record ID cdi_doaj_primary_oai_doaj_org_article_ea74ee8bfe754a35aed51313fc821cc2
Library Location Available Online
Date 1401
Sample Text Malignant pleural effusion is one of the most common complications of advanced malignancies, leading to decreased quality of life and life expectancy. With the advent of new therapies, patients with malignant pleural effusion appear to be living longer than previously thought. In this cohort study,26 patients, with malignant pleural effusion at the initial diagnosis of primary cancer, who were referred to the Lung Cancer Clinic of Shahid Motahari Clinic affiliated with Shiraz University of Medical Sciences , were studied Information on age, sex, tumor type, mortality, survival rate after malignant pleural effusion, EGFR mutation (in lung cancer patients), and metastasis were evaluated. In the present study, 12 patients (46.2%) were male and 14 patients (53.8%) were female. The median survival of patients was 2 years (interquartile range 1-3 years). Five patients (19.2%) had breast cancer, 19 patients (77.1%) had lung cancer, and two patients (7.7%) had lymphoma. The highest survival after diagnosis was related to one of the lymphoma patients (five years). In lung and breast cancer patients, the median survival was two years (interquartile range 1.5, 3) and one year (interquartile range 1, 2.5), respectively. Although the present study was a small single-center study, due to the appropriate lifespan of malignant pleural effusion patients with new therapies, more comprehensive studies are needed to re-evaluate the survival of patients with malignant pleural effusion.
Universitat de Girona - Ottoman library catalog search
Universitat de Girona You are being redirected...

Please wait